International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Janssen Initiates First-of-its-kind Clinical Study to Bridge Critical Gaps in Care for People of Color With Moderate to Severe Plaque Psoriasis

news_janssen blog image
More than 8 million Americans experience the physical, psychological, and emotional toll of psoriasis, but people of color experience additional challenges due to limited medical research, education, and underrepresentation in clinical studies. To help address these critical gaps, the Janssen Pharmaceutical Companies of Johnson & Johnson announced the initiation of VISIBLE. VISIBLE is a first-of-its-kind, large-scale prospective clinical study dedicated to generating key disease insights among Black, Hispanic, Asian, Indigenous, and other people of color. This study reinforces Janssen’s commitments to inclusive clinical research and addressing health inequities.
Janssen J & J logo

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Categories

Recent Posts

Getting to Know IPC’s Board Member Claudia de la Cruz: What Inspired Me to Specialize in Psoriasis

Introducing Our Latest IPC Councilors: Experts in Psoriasis Treatment and Research

Shining a Spotlight: Catching up with 2018 IPC Fellow, Jia Qi Chen, PhD

Also Read

disease relapse

Focus on Psoriasis: A Report from the 32nd European Academy of Dermatology and Venereology 2023 Congress (EADV)

Access the latest insights from the 32nd European Academy of Dermatology and Venereology 2023 Congress (EADV) in Berlin, Germany. This report covers significant updates on psoriasis, including the International Psoriasis Council’s Symposium and late-breaking sessions. Download the full EADV Congress Report for a comprehensive overview of psoriasis presentation and treatment advancements.

Read More
Blog - Commentary - Alexander Egeberg - graphic
long-term treatment

Commentary: Looking Beyond Plaque Psoriasis: Novel IL-36 Inhibitor for Prevention of Generalized Pustular Psoriasis Flares

Discover the latest in generalized pustular psoriasis (GPP) treatment with the approval of intravenous spesolimab by regulatory authorities. Read about a 48-week study on the subcutaneous delivery of spesolimab, showcasing promising results for preventing GPP flares. Learn about the evolving landscape of GPP treatment.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.